

Certificate of Analysis for MRA-925

Plasmodium falciparum, Strain GB4

Catalog No. MRA-925

This reagent is the tangible property of the U.S. Government.

Product Description: Plasmodium falciparum (P. falciparum), strain GB4 was cloned in 2000 from the Ghana III/CDC strain, originally isolated by the Centers for Disease Control and Prevention from a patient (hospitalized in Georgia, USA) who had acquired the infection in Ghana.

Lot¹: 70006878 Manufacturing Date: 22SEP2017

TEST	SPECIFICATIONS	RESULTS		
Identification by Giemsa Stain Microscopy ^{2,3}	Blood-stage parasites present	Blood-stage parasites present		
Antimalarial Susceptibility Profile (in vitro) ² Half-maximal Inhibitory Concentration (IC50) by SYBR green I® drug sensitivity assay ⁴ Chloroquine Artemisinin Quinine Cycloguanil Pyrimethamine Sulfadoxine	Report results	24.9 ± 1.1 nM 10.9 ± 0.3 nM 72.7 ± 3.3 nM 9.9 ± 0.7 nM 42.1 ± 3.9 nM 553400 ± 38258 nM		
Genotypic Analysis ² Sequencing of Merozoite Surface Protein 2 (MSP2) gene (~ 590 base pairs)	Consistent with <i>P. falciparum</i>	Consistent with <i>P. falciparum</i> (Figure 1)		
Functional Activity by PCR Amplification ² MSP2 PCR amplicon analysis ⁵	~ 600 to 900 base pair amplicon	~ 800 base pair amplicon		
Level of Parasitemia Pre-freeze ^{6,7} Ring-stage parasitemia Total parasitemia Post-freeze ^{2,8} Ring-stage parasitemia Total parasitemia	Report results ≥ 2% Report results ≥ 1%	2.46% 3.38% 1.66% 3.56%		
Viability ^{2,9}	Growth in infected red blood cells	Growth in infected red blood cells		
Sterility (21-day incubation) ² Harpo's HTYE broth ¹⁰ , 37°C and 26°C, aerobic Tryptic Soy broth, 37°C and 26°C, aerobic Sabouraud Dextrose broth, 37°C and 26°C, aerobic DMEM with 10% FBS, 37°C, aerobic Sheep Blood agar, 37°C, aerobic Sheep Blood agar, 37°C, anaerobic Thioglycollate broth, 37°C, anaerobic	No growth	No growth		
Mycoplasma Contamination ² DNA Detection by PCR	None detected	None detected		

MRA-925 was produced by cultivation of BEI Resources MR-MRA-925 lot 58422569 in fresh human erythrocytes suspended in RPMI 1640 medium, adjusted to contain 10% (v/v) heat-inactivated human serum (pooled Type A), 25 mM HEPES, 2 mM L-glutamine, 4 g/L D-glucose, 0.005 μg/mL hypoxanthine and 2.5 μg/mL gentamicin. The culture was incubated at 37°C in sealed flasks outgassed with blood-gas atmosphere (90% N₂, 5% CO₂, 5% O₂) and monitored for parasitemia daily for 9 days. Every 1 to 2 days, uninfected, leukocyte filtered, Type O erythrocytes in complete culture medium were added dropwise to the culture as needed and monitored for hematocrit.

²Testing completed on vialed post-freeze material.

BEI Resources

www.beiresources.org

E-mail: contact@beiresources.org

Tel: 800-359-7370 Fax: 703-365-2898



Certificate of Analysis for MRA-925

Figure 1: MRA-925 MSP2 Sequence

TTAAAAATGA	AAGTAAATAT	AGCAACACAT	TCATAAACAA	TGCTTATMAT	ATGAGTATAA	GGAGAAGTAT	GGCAGAAAGT
AAGACTCCTA	CTGGTACTGG	TGCTAGTGGT	AATCCTCCTG	CTGGTGCTGG	TGCTAGTGGT	AATCCTCCTG	CTGGTGCTGG
TGCTAGTGGT	AATCCTCCTG	CTGGTGCTGG	TGCTAGTGGT	AATCCTCCTG	CTGGTGCTGG	TGCTAGTGGT	AATCCTCCTG
CTGGTGCTGG	TGCTAGTGGT	AATCCTCCTG	CTGGTGCTGA	GAGAAGTCCA	AGTACTACCA	CAACTACCAC	AACTACCACA
ACTACTAATG	ATGCAGAAGC	ATCTACCAGT	ACCTCTTCAG	AAAATCCAAA	TCATAATAAT	GCCAAAACAA	ATCCAAAAGG
TAATGGAGGA	GTTCAAGAAC	CAAATAAAGC	AAATACAGAA	ACTCAAAATA	ACTCAAATGT	TCAACAAGAC	TCTCAAACTA
AATCAAATGT	TCCACCCACT	CAAGATGCAG	ACACTAAAAG	TCCTACTGCA	CAACCTGAAC	AAGCTGAAAA	TTCTGCTCCA
ACAGCCGAAC	AAACTGAATC	CCCCGAATTA	CAATCTGCAC	CAGAGAATAA	AGGTACAGGA	CAACATGGAC	ATATGCATGG
TTCTAGAAAT	AATCATCCAC	AAAATACTTC	TGATAGTCAA	AAAGAATGTA	CCGATGGTAA	CAAAGAAAAC	TGTGGAGCAG
CAACATCCCT	CTTAAATAAC	TCTAGTAATA	TTGCTTCAAT	AAATAAAT			

/Heather Couch/

Heather Couch 29 AUG 2018

Program Manager or designee, ATCC Federal Solutions

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

Support Provided by NIAID

BEI Resources
www.beiresources.org

E-mail: contact@beiresources.org
Tel: 800-359-7370

Fax: 703-365-2898

³Blood-stage malaria parasites (rings, trophozoites, schizonts +/- gametocytes) were examined by microscopic Giemsa-stained blood smears of an *in vitro* human blood culture over 4 days.

⁴A SYBR Green I[®] anti-malarial drug sensitivity assay in 96-well plates was used to determine IC₅₀ values of an active (> 70% ring stage) parasite culture in the presence of each antimalarial drug [Hartwig, C. L., et al. "XI: I. SYBR Green I[®]-Based Parasite Growth Inhibition Assay for Measurement of Antimalarial Drug Susceptibility in *Plasmodium falciparum*." In <u>Methods in Malaria Research Sixth Edition</u>. (2013) Moll, K., et al. (Ed.), EVIMalaR, pp. 122-129. Available at: https://www.beiresources.org/Publications/MethodsinMalariaResearch.aspx].

⁵Primer sequences and conditions for PCR are available upon request.

⁶Testing completed on bulk material prior to vialing and freezing.

⁷Parasitemia was determined after 9 days post infection by microscopic counts of Giemsa-stained blood smears.

⁸Post-freeze parasitemia was determined after 4 days post infection by microscopic counts of Giemsa-stained blood smears.

⁹Viability was confirmed by examination of infected erythrocytes for parasitemia at 4 days post infection.

¹⁰Atlas, Ronald M. <u>Handbook of Microbiological Media</u>. 3rd ed. Ed. Lawrence C. Parks. Boca Raton: CRC Press, 2004, p. 798.